Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

Potential association between senescence and aging in COVID-19

A review published in Cells discussed characteristics of cellular senescence and its potential role in COVID-19.

9 Dec 2021

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.

9 Dec 2021

Equilibrium simulation of SARS-CoV-2 spike protein highlights its global conformational characteristics

A team of researchers set out to build a full-length, membrane-embedded spike to study its conformational dynamics at the atomic level using molecular dynamics simulations to understand better how this important component of the virus machinery works.

8 Dec 2021

Estimating transmission heterogeneity dynamics of SARS-CoV-2 in Massachusetts

Researchers propose an analytical framework and two methodologies for estimating transmission heterogeneity dynamics in this paper.

8 Dec 2021

Colorimetric detection of SARS-CoV-2 viral RNA by an in vitro transcription/translation assay

This work has emphasized the clinical and translational potential of paper-based biosensors.

6 Dec 2021

SARS-CoV-2 immune memory in mRNA vaccine recipients

Researchers measured SARS-CoV-2–specific antibody, memory B cell, and memory T cell responses in a group of healthy subjects who generated primary immune responses to two doses of mRNA vaccine compared to a group of SARS-CoV-2–recovered vaccines.

6 Dec 2021

Equipment-free handheld microfluidic injection provides visible readout of SARS-CoV-2 detection

In this paper, a group of researchers from Harvard Medical School, McGill University, and Tianjin University describes an on-chip diagnostic technology for the direct detection of SARS-CoV-2 N protein in nasal samples that combines the advantages of hydrodynamic microfluidic filtration and sandwich immunoassay.

5 Dec 2021